SAN DIEGO, Feb. 13, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at several upcoming investor conferences.
Vical will present on Wednesday, February 15, at 10:30 a.m. EST at the Leerink Swann 2012 Global Healthcare Conference (New York, February 15 – 16).
Vical will present on Monday, February 27, at 3:30 p.m. EST at the Citi 2012 Global Health Care Conference (New York, February 27 – 29).
Vical will participate in a panel discussion, The Future of Immunotherapy; Key Phase III Trials to Watch," on Wednesday, February 29, at 11:00 a.m. EST at the 2012 RBC Global Healthcare Conference (New York, February 28 – 29).
A webcast of the company's presentation at the Citi conference will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT: Alan R. Engbring
Source: Vical Incorporated